Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells

Hsin-Kai Liao, Ying Gu, Arturo Diaz, John Marlett, Yuta Takahashi, Mo Li, Keiichiro Suzuki, Ruo Xu, Tomoaki Hishida, Chan-Jung Chang, Concepcion Rodriguez Esteban, John Young and Juan Carlos Izpisua Belmonte ()
Additional contact information
Hsin-Kai Liao: Gene Expression Laboratory, Salk Institute for Biological Studies
Ying Gu: Gene Expression Laboratory, Salk Institute for Biological Studies
Arturo Diaz: Nomis Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies
John Marlett: Nomis Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies
Yuta Takahashi: Gene Expression Laboratory, Salk Institute for Biological Studies
Mo Li: Gene Expression Laboratory, Salk Institute for Biological Studies
Keiichiro Suzuki: Gene Expression Laboratory, Salk Institute for Biological Studies
Ruo Xu: Biophysics and Molecular Biology, Iowa State University
Tomoaki Hishida: Gene Expression Laboratory, Salk Institute for Biological Studies
Chan-Jung Chang: Gene Expression Laboratory, Salk Institute for Biological Studies
Concepcion Rodriguez Esteban: Gene Expression Laboratory, Salk Institute for Biological Studies
John Young: Nomis Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies
Juan Carlos Izpisua Belmonte: Gene Expression Laboratory, Salk Institute for Biological Studies

Nature Communications, 2015, vol. 6, issue 1, 1-10

Abstract: Abstract To combat hostile viruses, bacteria and archaea have evolved a unique antiviral defense system composed of clustered regularly interspaced short palindromic repeats (CRISPRs), together with CRISPR-associated genes (Cas). The CRISPR/Cas9 system develops an adaptive immune resistance to foreign plasmids and viruses by creating site-specific DNA double-stranded breaks (DSBs). Here we adapt the CRISPR/Cas9 system to human cells for intracellular defense against foreign DNA and viruses. Using HIV-1 infection as a model, our results demonstrate that the CRISPR/Cas9 system disrupts latently integrated viral genome and provides long-term adaptive defense against new viral infection, expression and replication in human cells. We show that engineered human-induced pluripotent stem cells stably expressing HIV-targeted CRISPR/Cas9 can be efficiently differentiated into HIV reservoir cell types and maintain their resistance to HIV-1 challenge. These results unveil the potential of the CRISPR/Cas9 system as a new therapeutic strategy against viral infections.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms7413 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms7413

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms7413

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().